| Date | Title | Description |
| 25.08.2026 | Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases | SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 24.08.2026 | Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D | SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 11.08.2026 | Quantified Named One of the Fastest-Growing AI & Data Companies on the Inc. 5000 List for the Second Consecutive Year | For the second consecutive year, Quantified lands on the Inc. 5000 list, fueled by growing adoption among top global pharma companies looking to keep commercial teams compliant, certified, coached, and ready to perform.
AUSTIN, Texas, Aug. ... |
| 06.08.2026 | Manufacturing Jobs Flock to the U.S. Thanks to President Trump’s America First Economic Agenda | With President Trump’s economic agenda taking effect, the United States is seeing an economic revival across our manufacturing industry. July saw the strongest expansion in domestic manufacturing activity in more than four years, marking se... |
| 04.08.2026 | Gradientech appoints Sumi Thaker as Chief Executive Officer to lead its next phase of commercial growth | Gradientech appoints Sumi Thaker as Chief Executive Officer to lead its next phase of commercial growth
Tue, Aug 04, 2026 17:24 CET Report this content
Gradientech, a diagnostics company pioneering ultra-rapid antibiotic susceptibility test... |
| 28.07.2026 | Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle | Norstella, the leading global provider of AI-enabled pharma intelligence solutions, announced the launch of the Pipeline-to-Patient Productivity Index, an annual benchmark measuring R&D productivity, market access, and commercial return... |
| 20.07.2026 | Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026 | SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 13.07.2026 | Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB | SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 22.06.2026 | Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE | ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ... |
| 17.06.2026 | China Is One of World's Most Dynamic, Innovative Markets, UCB CEO Says | (Yicai) June 17 -- China is one of the most dynamic and innovative markets in the world, making it supportive and important for UCB, according to the chief executive of the Belgium-rooted global biopharmaceutical company..
"For us at U... |
| 12.06.2026 | Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 12, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther... |
| 12.06.2026 | UCB Transforms Safety Operations with Veeva Safety Suite in Collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions | WASHINGTON, June 12, 2026 /PRNewswire/ -- ELIQUENT Life Sciences ("ELIQUENT") today announced the June 1 go-live of Veeva Safety Suite at UCB. As one of the first organizations to adopt the complete suite, UCB is unifying its glob... |
| 10.06.2026 | Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China | SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 08.06.2026 | Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance | SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 03.06.2026 | Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026 | SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 01.06.2026 | Secretome Therapeutics Secures $30M, Propels Duchenne Cardiomyopathy Therapy | Secretome Therapeutics closed a $30 million Series A round led by RA Capital. This pivotal funding advances STM-01, an innovative therapy for Duchenne muscular dystrophy-associated cardiomyopathy. The nCPC-derived candidate targets inflamma... |
| 28.05.2026 | Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer | SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializin... |
| 28.05.2026 | Secretome Therapeutics: $30 Million Series A Raised To Advance Duchenne-Associated Cardiomyopathy Therapy | Secretome Therapeutics, a clinical-stage biotechnology company developing therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30 million Series A financing led solely by RA Capital Management. The fu... |
| 27.05.2026 | Three-year cooling-off period for UCB Directors may set in motion a game of musical chairs | - |
| 20.05.2026 | Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline | SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializin... |
| 08.03.2026 | China's Biopharma Ascendance: Two Mega Deals Reshape Global Drug Landscape | Chinese biopharma companies clinched huge global drug licensing deals. Sino Biopharm licensed its anti-fibrotic drug, Rovadicitinib, to Sanofi for $1.5 billion, addressing myelofibrosis and GVHD. Antengene granted UCB global rights for ATG-... |
| 04.03.2026 | Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases | Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.
Antengene will receive USD 80 million of u... |
| 04.03.2026 | Sino Biopharm Inks USD1.5 Billion Drug Licensing Deal With Sanofi | (Yicai) March 4 -- Sino Biopharmaceutical has licensed its newly approved anti-fibrotic drug to the French drugmaker Sanofi, saying it will receive as much as USD1.5 billion in return.
The agreement giving Paris-based Sanofi the global deve... |
| 03.02.2026 | MazeMap Acquires Thing Technologies to Build a Global Leader in Wayfinding and Space Intelligence | MazeMap Acquires Thing Technologies to Build a Global Leader in Wayfinding and Space Intelligence
Tue, Feb 03, 2026 09:00 CET Report this content
February 3, 2026 — MazeMap, Europe’s leading platform for wayfinding and space intelligence, t... |
| 02.02.2026 | 3 Ways Health Brands Can Design Digital Experiences That Users Won’t Abandon | According to new research, nearly half of users ultimately abandon the digital health or wellness technologies they adopt. This startling finding reveals a major challenge amid the industry’s rapid growth.
Health and wellness technologies a... |
| 02.02.2026 | Sixth Annual Seizure Action Plan Awareness Week to Promote Seizure Preparedness Nationwide, Feb. 9-16, 2026 | The Seizure Action Plan Coalition, a collaboration managed by Epilepsy Alliance America, will host the Sixth Annual Seizure Action Plan (SAP) Awareness Week from February 9–16, 2026. The national epilepsy awareness campaign focuses on seizu... |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | This is how exposed European Big Pharma is to the U.S. | The U.S. is the biggest single market for most pharma and biotech firms.
Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five get a majority of their total sales from the U.S.
AstraZeneca gets 42% of sales fr... |
| 15.12.2025 | uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials | On behalf of the Critical Path Institute (C-Path) Florence Mowlem PhD, led this much-needed project, providing 10 best practices for EDeD design and implementation to support clinical trial data capture, along with co-authors from Top 10 ph... |
| 10.12.2025 | Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights | Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufac... |
| 08.12.2025 | UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder | Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1
Holistic benefit: secondary endpoints showed si... |
| 28.11.2025 | American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement | ANS2025 served as a national platform for neurologists, primary care clinicians, nurses, and researchers to engage in high-impact education on the latest advancements in neurological care. The hybrid CME/CE event featured expert sessions on... |
| 18.11.2025 | Beacon Biosignals Secures $86M to Revolutionize Brain Disorder Treatment | Beacon Biosignals landed $86M in Series B funding. They plan to use it to improve diagnostics and treatment using AI. Their neurotechnology targets brain disorders. The funding helps them expand and accelerate discovery. This positions them... |
| 16.11.2025 | Beacon Biosignals: $86 Million Series B Raised To Advance AI-Driven Neurodiagnostics And Precision Neuroscience | Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagn... |
| 13.11.2025 | Beacon Biosignals Raises $86M in Series B Funding | Beacon Biosignals, a Boston, MA-based neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, raised $86m in Series B funding.
Backers included Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, ... |
| 29.09.2025 | European stocks close higher as pharma giants AstraZeneca and GSK notch gains | Stocks listed in Europe closed higher on Monday, as investors monitored the impact of a potential U.S. government shutdown later in the week.
The pan-European Stoxx 600 provisionally ended up around 0.34%, with most sectors and major bourse... |
| 19.09.2025 | Paris-based Juisci raises €5.5 million to transform how healthcare professionals access scientific knowledge | France’s Juisci, a HealthTech startup that transforms the way healthcare professionals consume scientific knowledge, has secured €5.5 million in Seed funding in order to boost R&D, scale its team, and accelerate international expansion,... |
| 16.09.2025 | Bristol Myers Sells Out of First US Drugs Joint Venture in China | (Yicai) Sept. 16 -- Bristol Myers Squibb has sold its controlling stake in what was the first American ian pharmaceuticals joint venture to be set up in China, as part of the drugmaker’s repositioning of global resources and regional strate... |
| 29.08.2025 | UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress | 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA®▼... |
| 19.06.2025 | SpliceBio: $135 Million Series B Raised For Expanding Pipeline Of Genetic Medicines | SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the closing of a $135 million Series B financing co-led by new investors EQT Life Sciences a... |
| 11.06.2025 | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
Wed, Jun 11, 2025 09:30 CET Report this content
Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as... |
| 06.06.2025 | Expert: Build solid technology barriers to eliminate risks | Liu Mingjuan, a leading expert on compliance management, calls on enterprises to establish effective risk management mechanism in the global environment during the Thirteenth China International Anti-corruption Compliance Summit held on May... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 28.02.2025 | PeopleCare.Ai and Patients Rising Launch New Program for Myasthenia Gravis Patients | Program delivers evidence based solution to get better outcomes for rare disease patients through Peoplecare.ai's Wellspace digital platform.
By combining Patients Rising's deep expertise in patient advocacy with our AI-powered platform, we... |
| 09.01.2025 | UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform | Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process
These advancements have the potential to transform antibody discovery methods, broadening therapeutic ap... |
| 06.01.2025 | Executive reshuffle in four startups |
As of this year, Ulrich Harmuth is the Chief Executive Officer at betterview, which has since its inception in 2021 established itself as the market leader in refractive surgery. The company has performed over 15,000 successful treatments.... |
| 13.12.2024 | Procurement in 2025: From ‘should we try AI?’ to ‘When can we start?’ | A July 2024 Gartner survey found that 72% of procurement leaders are prioritising the integration of GenAI into their strategies. Gartner predicts that as AI agents become more embedded in procurement technology, they will transform the rol... |
| 30.11.2024 | The Surge of Private Equity in India’s Financial Services: A New Era of Investment | India's financial services sector is a vibrant landscape, teeming with opportunity. Private equity (PE) investors are flocking to this market, eager to carve out their share of the pie. The recent surge in investments is not just a trend; i... |
| 30.11.2024 | CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China | CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million.
New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry.
Strate... |
| 19.11.2024 | Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity | Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed acro... |
| 15.09.2024 | Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together | PISCATAWAY, N.J., Sept. 15, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a ... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 28.08.2024 | Navigating the Crossroads: UCB's Strategic Shift and Naspers' Regulatory Plea | In the fast-paced world of pharmaceuticals and digital platforms, two stories emerge that highlight the challenges and opportunities within their respective sectors. UCB, a Belgian pharmaceutical giant, is selling its neurology and allergy ... |
| 26.08.2024 | Mubadala, CBC Group to buy UCB's Chinese neurology and allergy business for $680m | Abu Dhabi sovereign investor Mubadala Investment Company and Asia healthcare-focused asset management firm CBC Group will acquire a 100% stake in UCB Pharma’s neurology and allergy business in China for $680 million. |
| 26.08.2024 | UCB to Sell China Neurology, Allergy Business to Mubadala, CBC for USD680 Million | (Yicai) Aug. 26 -- UCB said Abu Dhabi sovereign wealth fund Mubadala Investment and CBC Group, Asia's largest healthcare-focused investment firm, will buy the Belgian drugmaker's mature neurology and allergy business in China for USD680 mil... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 13.08.2024 | Takeda, Roche, and Genentech Recognized by the Healthcare Businesswomen's Association for Advancing Women in the Workplace Initiatives | UCB Transformational Program Also Honored
FAIRFIELD, N.J., Aug. 13, 2024 /PRNewswire/ -- To showcase the impactful commitment and outcomes of equitable practices for women in the workplace, the Healthcare Businesswomen's Association (HBA) t... |
| 01.08.2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Pivotal AUGME... |
| 26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
| 26.07.2024 | BioVaxys and American Skin Association: Pioneering Paths in Medical Research**
** | ** In the ever-evolving landscape of medical research, two organizations stand out: BioVaxys Technology Corp. and the American Skin Association (ASA). Each is carving a niche in their respective fields, focusing on innovative solutions for ... |
| 22.07.2024 | AMERICAN SKIN ASSOCIATION ANNOUNCES 2024 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES | NEW YORK, July 22, 2024 /PRNewswire/ -- American Skin Association has announced the names of the three Investigative Scientist Awards. Andrew Ji, MD of Icahn School of Medicine at Mount Sinai was awarded the ASA Sanofi Investigative Scienti... |
| 12.07.2024 | AI-driven sourcing cuts costs by 20% for Global 2000 firms | New research published by Globality has found that AI-driven autonomous sourcing can reduce costs by 20% and increase productivity by 70% among Global 2000 companies. The study, conducted by HFS Research in collaboration with Globality, hig... |
| 02.07.2024 | India's Biggest Gifting Exhibition, Gifts World Expo 2024, to Premiere in New Delhi for its 25th Milestone Edition | New Delhi, Delhi, India
Gifts World Expo (GWE), the comprehensive tradeshow on gifting and promotional solutions, is all set to make its comeback with its 25th edition at Pragati Maidan, New Delhi from 25th to 27th July 2024. Organized by M... |
| 26.05.2024 | Stress and Skin: A Complex Relationship | Stress can be a silent killer, not just for your mental health but also for your skin. Dermatologists reveal the hidden connection between stress and skin problems, shedding light on how our emotions can manifest physically.
Stress is like ... |
| 20.05.2024 | Studies Show Linked Biological Pathways Driving Skin Inflammation | NEW YORK, May 20, 2024 /PRNewswire/ -- A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all inf... |
| 08.05.2024 | Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update | – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 –
– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 15.01.2024 | UCB Japan Co., Ltd. Notice of renewal of “Rheumatology WoCBA Net” | - |
| 15.01.2024 | UCB Japan Co., Ltd. Notice of renewal of “Rheumatology WoCBA Net” | [UCB Japan Co., Ltd.] Notice of renewal of “Rheumatology WoCBA Net”
*View in browser* *UCB Japan Co., Ltd.*
Press release: January 15, 2024
**
Announcement of renewal of “Rheumatology WoCBA Net”
*Information site for all female rheumatoid a... |
| 18.10.2023 | In Same Day, UCB Lands Two FDA Drug Approvals in Autoimmune Diseases | A UCB drug with a novel approach to plaque psoriasis won a long-awaited FDA approval, positioning it to bring patients a new choice in a crowded market of products for the prevalent skin condition. The Belgian drugmaker on Wednesday also wo... |
| 26.09.2023 | Is Belgian Biotechnology Reshaping Global Healthcare and Pharmaceutical Industry? | Key Takeaways:
UCB is a Belgium-based biopharmaceutical and specialty chemical company that specializes in diseases of the central nervous system and immunology.
The company’s focus areas include epilepsy, diabetic neuropathic pain, multipl... |
| 18.03.2023 | Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks | Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements over placebo in signs and symptoms of hidradenitis suppurativa at week 16, as measu... |
| 07.02.2023 | J&J Drug for Rare Infant Blood Disorder Achieves Main Goal of Phase 2 Test | Johnson & Johnson drug nipocalimab is in late-stage clinical testing in a rare neuromuscular disorder, and if it stays on track could become the third-to-market drug in its class for that indication. But the pharmaceutical giant now has... |
| 21.12.2022 | AI In Big Pharma: The First Antibody Designed Using AI In The Clinic | Terry Baker (right) and Jiye Shi were appointed UCB Fellows for their contributions to the design of ... [+] Bimekizumab Dr. Jiye Shi |
| 28.10.2022 | GliaPharm and UCB enter drug discovery research collaboration | |
| 25.03.2022 | UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022 | *** Unofficial English translation – For convenience purposes only ***
UCB SA/NV - Public Limited Liability Company
Allée de la Recherche 60, 1070 Brussels
Enterprise nr. 0403.053.608 (RLE Brussels)
www.ucb.com
("UCB SA/NV" or the... |
| 14.02.2022 | UCB : Launch of the DCTx Innovation Incubator - Partnering in innovations that positively benefit patients, society and the world | The Digital Care Transformation (DCTx) team at UCB is delighted to officially announce the launch of the DCTx Incubator. Over the last few months, we have been engaging with the global healthcare ecosystem, seeking out the best innovations ... |
| 04.02.2022 | UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results | BRUSSELS and ATLANTA, Feb. 4, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) triali evaluating its investigational treatment zilucoplan, a self-administere... |
| 21.01.2022 | Yingli Pharma brings small molecule research to the US in new pact with MD Anderson; UCB's psoriatic arthritis drug shows positive PhIII results | Shanghai biotech Yingli Pharma wants to bring its small molecule drug research global — and a new pact with MD Anderson will help it get there.
Yingli and MD Anderson have inked a 5-year collaboration deal that will put its ca... |
| 19.01.2022 | UCB Media Room: UCB to acquire Zogenix | https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg ** UCB to acquire Zogenix ------------------------------------------------------------ =C2=B7 Transaction broadens and builds upon UCB=E2=80=99s role as a leader = in, and our... |
| 19.01.2022 | UCB to acquire Zogenix | BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under whi... |
| 13.01.2022 | UCB : Why we have built our future on creating sustainable value for all stakeholders | The COVID-19 pandemic has reminded us that life is what happens. Success requires us to reflect on the trends surrounding us and be ready to act.
The focus on agility - together with our partnerships - was the key theme running through our ... |
| 10.01.2022 | UCB Media Room: Disposals of own shares | https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg ** Disposals of own shares ------------------------------------------------------------ Brussels (Belgium), 8 January 2022 =E2=80=93 20:00 (CET) =E2=80=93 regulate= d informat... |
| 23.12.2021 | UCB Digital Care Transformation (DCTx) Incubator: partnering in innovations that positively benefit patients, society and the world. | UCB will be launching a digital health incubation program.
We want to partner to help accelerate innovative digital health solutions.
Meet and get in touch with some of the leading voices in our team.
UCB Digital Care Transformation (DCTx) ... |
| 21.12.2021 | Big Tech Countdown Day 1: Microsoft’s top 5 healthcare moves in 2021 | Here’s a look back at Microsoft’s top 5 healthcare moves since the start of the year—and why they’ll be significant for its growth in 2022.
1. Microsoft secured major health system and pharma partnerships in February.
Microsoft expanded its... |
| 10.12.2021 | UCB : announces positive Phase 3 results for rozanolixizumab in generalized … | · Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalized myasthenia gravis (gMG)
· Study met primary and all secondary endpoints with statistical significance
·... |
| 10.12.2021 | UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis | BRUSSELS, Dec. 10, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab, a subcutaneously (SC) infused monoclonal antibody targeti... |
| 08.12.2021 | UCB : Unleashing the Power of Digital Solutions in Epilepsy Care | As patient care continues to evolve, so does UCB - embracing advances in technology to help keep us more connected to the patients we serve and allow us to develop new holistic approaches to deliver optimal care to patients. As leaders in n... |
| 06.12.2021 | UCB : Bringing diverse mindsets together to meet patient needs | Over the last few years, the pharmaceutical industry has begun to recognise the importance of fostering a diverse, inclusive, and culturally intelligent environment. Additionally, throughout our industry, there is a unified drive to ensure ... |
| 03.12.2021 | UCB : Disposals of own shares | Brussels (Belgium), 3 December 2021 - 20:00 (CET) - regulated information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exer... |
| 03.12.2021 | Working Toward a More Equitable Future: Addressing Barriers in the … | Epilepsy, an often life-altering disease involving unprovoked seizures over time, affects an estimated 50 million people globally and often requires specialized care and medical treatment. In the US, Hispanics are one of the largest subpopu... |
| 02.12.2021 | Novartis boosts neuro pipeline through alliance on UCB Parkinson’s drugs | The field of Parkinson’s drug research includes many companies developing therapies addressing a toxic protein linked to the progression of the disease, and Novartis is joining the chase via an alliance with UCB. Novartis has agreed to pay ... |
| 30.11.2021 | UCB : and Chiesi enter global license agreement for zampilimab a … | · UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases
· UCB will receive upfront payment... |
| 26.11.2021 | UCB : Disposals of own shares | Brussels (Belgium), 26 November 2021 - 20:00 (CET) - regulated information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exe... |
| 19.11.2021 | UCB : Disposals of own shares | Brussels (Belgium), 19 November 2021 - 20:00 (CET) - regulated information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exe... |
| 18.11.2021 | UCB : Unique patient-led study into life with myasthenia gravis published … | Posted by
Kenza Seddik, Patient Value Neurology & Europe/International Solutions
18-Nov-2021
Myasthenia gravis (MG) is a chronic neuromuscular condition, with an annual incidence of 8 - 10 cases for every 1 million, which can occur at a... |
| 15.11.2021 | UCB : Disposals of own shares | Brussels (Belgium), 15 November 2021 - 20:00 (CET) - regulated information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exe... |